Tags

Type your tag names separated by a space and hit enter

Assessing brain-derived neurotrophic factor as a novel clinical marker of endometriosis.
Fertil Steril. 2016 Jan; 105(1):119-28.e1-5.FS

Abstract

OBJECTIVE

To evaluate novel clinical markers of endometriosis including the neurotrophins brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and neurotrophin 4/5 (NT4/5) and compare them to others previously reported in the literature including cancer antigen 125 (CA-125) and C-reactive protein (CRP).

DESIGN

Prospective study.

SETTING

University hospital.

PATIENT(S)

One hundred thirty-eight women were prospectively and consecutively recruited (April 2011-April 2015; cases: undergoing endometriosis surgery, n = 96; controls: benign gynecological surgery, n = 24 combined with healthy women, no history of pelvic pain, not undergoing surgery, n = 18).

INTERVENTION(S)

Collection of peripheral blood, gynecological and demographic information, eutopic biopsy in women undergoing laparoscopy.

MAIN OUTCOME MEASURE(S)

Circulating BDNF, NGF, NT4/5, CA-125, and CRP were quantified by ELISA.

RESULT(S)

Plasma concentrations of BDNF were significantly greater in women with endometriosis (1,091.9 pg/mL [640.4-1,683.1]; n = 68, untreated) than in controls (731.4 pg/mL [352.1-1,176.2]; n = 36), whereas circulating NGF, NT4/5, CA-125, and CRP were not different. When assessed for their ability to differentiate between women with revised Classification of the American Society of Reproductive Medicine stage 1 and 2 or stage 3 and 4 disease and controls, BDNF was the only putative marker able to identify stage 1 and 2 disease, with a sensitivity and specificity of 91.7% and 69.4%, respectively, using an arbitrary cutoff value of 1,000 pg/mL. We also demonstrated that circulating BDNF in women with endometriosis who were receiving ovarian suppression for disease was equivalent to that in the control group. This suggests that BDNF may also offer the opportunity to monitor patient response to treatment.

CONCLUSION(S)

Plasma BDNF is a potentially useful clinical marker of endometriosis that is superior to NGF, NT4/5, CA-125, and CRP.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, McMaster University, Hamilton, Ontario, Canada.Department of Obstetrics and Gynecology, McMaster University, Hamilton, Ontario, Canada.Department of Obstetrics and Gynecology, McMaster University, Hamilton, Ontario, Canada.Department of Reproductive Medicine, University of California, San Diego, La Jolla, California.Department of Obstetrics and Gynecology, McMaster University, Hamilton, Ontario, Canada. Electronic address: fosterw@mcmaster.ca.

Pub Type(s)

Comparative Study
Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26409150

Citation

Wessels, Jocelyn M., et al. "Assessing Brain-derived Neurotrophic Factor as a Novel Clinical Marker of Endometriosis." Fertility and Sterility, vol. 105, no. 1, 2016, pp. 119-28.e1-5.
Wessels JM, Kay VR, Leyland NA, et al. Assessing brain-derived neurotrophic factor as a novel clinical marker of endometriosis. Fertil Steril. 2016;105(1):119-28.e1-5.
Wessels, J. M., Kay, V. R., Leyland, N. A., Agarwal, S. K., & Foster, W. G. (2016). Assessing brain-derived neurotrophic factor as a novel clinical marker of endometriosis. Fertility and Sterility, 105(1), 119-e1-5. https://doi.org/10.1016/j.fertnstert.2015.09.003
Wessels JM, et al. Assessing Brain-derived Neurotrophic Factor as a Novel Clinical Marker of Endometriosis. Fertil Steril. 2016;105(1):119-28.e1-5. PubMed PMID: 26409150.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Assessing brain-derived neurotrophic factor as a novel clinical marker of endometriosis. AU - Wessels,Jocelyn M, AU - Kay,Vanessa R, AU - Leyland,Nicholas A, AU - Agarwal,Sanjay K, AU - Foster,Warren G, Y1 - 2015/09/25/ PY - 2015/06/15/received PY - 2015/09/01/revised PY - 2015/09/02/accepted PY - 2015/9/27/entrez PY - 2015/9/27/pubmed PY - 2016/5/12/medline KW - Biomarker KW - C-reactive protein KW - CA-125 KW - endometriosis KW - neurotrophin SP - 119-28.e1-5 JF - Fertility and sterility JO - Fertil. Steril. VL - 105 IS - 1 N2 - OBJECTIVE: To evaluate novel clinical markers of endometriosis including the neurotrophins brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and neurotrophin 4/5 (NT4/5) and compare them to others previously reported in the literature including cancer antigen 125 (CA-125) and C-reactive protein (CRP). DESIGN: Prospective study. SETTING: University hospital. PATIENT(S): One hundred thirty-eight women were prospectively and consecutively recruited (April 2011-April 2015; cases: undergoing endometriosis surgery, n = 96; controls: benign gynecological surgery, n = 24 combined with healthy women, no history of pelvic pain, not undergoing surgery, n = 18). INTERVENTION(S): Collection of peripheral blood, gynecological and demographic information, eutopic biopsy in women undergoing laparoscopy. MAIN OUTCOME MEASURE(S): Circulating BDNF, NGF, NT4/5, CA-125, and CRP were quantified by ELISA. RESULT(S): Plasma concentrations of BDNF were significantly greater in women with endometriosis (1,091.9 pg/mL [640.4-1,683.1]; n = 68, untreated) than in controls (731.4 pg/mL [352.1-1,176.2]; n = 36), whereas circulating NGF, NT4/5, CA-125, and CRP were not different. When assessed for their ability to differentiate between women with revised Classification of the American Society of Reproductive Medicine stage 1 and 2 or stage 3 and 4 disease and controls, BDNF was the only putative marker able to identify stage 1 and 2 disease, with a sensitivity and specificity of 91.7% and 69.4%, respectively, using an arbitrary cutoff value of 1,000 pg/mL. We also demonstrated that circulating BDNF in women with endometriosis who were receiving ovarian suppression for disease was equivalent to that in the control group. This suggests that BDNF may also offer the opportunity to monitor patient response to treatment. CONCLUSION(S): Plasma BDNF is a potentially useful clinical marker of endometriosis that is superior to NGF, NT4/5, CA-125, and CRP. SN - 1556-5653 UR - https://www.unboundmedicine.com/medline/citation/26409150/Assessing_brain_derived_neurotrophic_factor_as_a_novel_clinical_marker_of_endometriosis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0015-0282(15)01889-0 DB - PRIME DP - Unbound Medicine ER -